4 completed, 3 recruiting, 2 active not recruiting, 1 available. 7 Not applicable, 3 Phase 2, 2 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Not applicable | 7 | Recruiting 3, Completed 2, Suspended 1, Unknown 1 |
| Phase 2 | 3 | Active not recruiting 1, Terminated 1, Withdrawn 1 |
| Phase 1 | 2 | Active not recruiting 2 |
Follow Small Bowel Cancer: new trials by email Literature Review of Small Bowel Cancer trials Research Report on Small Bowel Cancer
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Phase II Study of Adjuvant Immunotherapy Targeting KRAS G12D, KRAS G12V, or TP53 R175H for Participants With Advanced Gastrointestinal Malignancies KRAS TCR-Transduced PBL, Aldesleukin, Fludarabine - Gastrointestinal Carcinoma, Pancreatic Cancer | Phase 2 | Withdrawn | National Cancer Institute (NCI) | 2025-09-09 | 2025-09-11 | |
| Locally ablatIVe thErapy for oLigo-progressive gastrOintestiNal maliGnancies (LIVELONG) Ablative local therapy - Small Bowel Cancer, Colorectal Cancer | Not applicable | Recruiting | University of California, Davis | 300 | 2023-10-05 | 2026-07-02 |
| Individualized Dose Escalation of 5-FU for Gastrointestinal Cancer FOX dose-escalation algorithm - Colorectal Cancer, Esophagus Cancer | Not applicable | Recruiting | Dartmouth-Hitchcock Medical Center | 36 | 2023-07-14 | 2026-06-22 |
| Study of the Monoclonal Antibody IMT-009 in Patients With Advanced Solid Tumors or Lymphomas IMT-009, Fruquintinib - Non Small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma | Phase 1 / Phase 2 | Active not recruiting | Immunitas Therapeutics | 67 | 2022-11-28 | 2025-10-16 |
| Intraperitoneal Aerosolized Nanoliposomal Irinotecan (Nal-IRI) in Peritoneal Carcinomatosis From Gastrointestinal Cancer PIPAC with Nal-IRI - Peritoneal Carcinomatosis, Peritoneal Metastases | Phase 1 | Active not recruiting | University Hospital, Ghent | 45 | 2022-11-21 | 2026-07-13 |
| Stereotactic Body Radiotherapy in Patients With Rare Oligometastatic Cancers (OligoRARE) Stereotactic body radiotherapy, Palliative RT - Gynecologic Cancer, Skin Cancer | Not applicable | Recruiting | European Organisation for Research and Treatment of Cancer - EORTC | 200 | 2021-06-10 | 2024-08-26 |
| The Registry of Oncology Outcomes Associated With Testing and Treatment Biomarker Testing (L), Systemic Treatment (T), Patient Reported Outcomes (P) - Adenocarcinoma, Adenocystic Carcinoma | Completed | Taproot Health | 167 | 2021-05-05 | 2024-12-18 | |
| Clinical Trial of a Novel Dose Adjustment Algorithm for Preventing Cytopenia-Related Delays During FOLFOX Chemotherapy Algorithm for cytopenia-related delay and dose-reduction of mFOLFOX chemotherapy - Colorectal Cancer, Gastric Cancer | Not applicable | Completed | Dartmouth-Hitchcock Medical Center | 52 | 2020-10-15 | 2025-10-06 |
| A Novel Patient Engagement Platform Among Patients With Gastrointestinal Malignancies patient engagement platform - Colon Cancer, Gastric Cancer | Not applicable | Completed | Sheba Medical Center | 126 | 2020-03-15 | 2022-04-28 |
| RCT of Mobile Apps & FitBit v. Usual Care Mobile health application and Fitbit + standard of care, Standard of care - Pancreatic Cancer, Gastric Cancer | Not applicable | Suspended | Weill Medical College of Cornell University | 107 | 2017-05-31 | 2026-09-28 |
| Surgery With Extended (D3) Mesenterectomy for Small Bowel Tumors Surgery with extended (D3) mesenterectomy for small bowel tumors - Small Bowel Cancer, Small Bowel Carcinoid Tumor | Not applicable | Unknown | Sykehuset i Vestfold HF | 150 | 2016-11-04 | 2023-01-04 |
| Effects of S-1 and Capecitabine on Coronary Artery Blood Flow S-1, Capecitabine, Oxaliplatin - Esophagus Cancer, Stomach Cancer | Phase 2 | Terminated | Heikki Joensuu | 20 | 2015-01-01 | 2018-08-28 |
| Prospective Analysis of Hypersensitivity Reactions to Oxaliplatin Colorectal Cancer, Esophageal Cancer | Completed | Dana-Farber Cancer Institute | 112 | 2009-02-01 | 2022-04-18 | |
| Expanded Access to Ulixertinib (BVD-523) in Patients With Advanced MAPK Pathway-Altered Malignancies Ulixertinib (BVD-523) - Pancreatic Cancer, Small Bowel Cancer | Available | xCures | 2026-06-04 |
Colorectal Neoplasms (9) · Esophageal Neoplasms (9) · Stomach Neoplasms (9) · Pancreatic Neoplasms (8) · Cholangiocarcinoma (6) · Appendiceal Neoplasms (5) · Colonic Neoplasms (5) · Rectal Neoplasms (4) · Head and Neck Neoplasms (3) · Liver Neoplasms (3) · Melanoma (3) · Urinary Bladder Neoplasms (3) · Bile Duct Neoplasms (2) · Carcinoma, Non-Small-Cell Lung (2) · Glioblastoma (2)
Colonic Diseases (13) · Digestive System Diseases (13) · Digestive System Neoplasms (13) · Gastrointestinal Diseases (13) · Intestinal Diseases (13) · Intestinal Neoplasms (13) · Neoplasms by Site (13) · Gastrointestinal Neoplasms (12) · Neoplasms (12) · Rectal Diseases (12) · Esophageal Diseases (9) · Stomach Diseases (9) · Endocrine Gland Neoplasms (8) · Endocrine System Diseases (8) · Neoplasms by Histologic Type (8)
Algorithms (1) · Biological Therapy (1) · Capecitabine (1) · Cyclophosphamide (1) · Drug Therapy (1) · HMPL-013 (1) · Immunotherapy (1) · Molecular Diagnostic Techniques (1) · Oxaliplatin (1) · Patient Reported Outcome Measures (1) · Quality of Life (1) · Radiosurgery (1) · S 1 (combination) (1) · Standard of Care (1) · Surgical Procedures, Operative (1)
Dartmouth-Hitchcock Medical Center (2) · Dana-Farber Cancer Institute (1) · European Organisation for Research and Treatment of Cancer - EORTC (1) · Heikki Joensuu (1) · Immunitas Therapeutics (1) · National Cancer Institute (NCI) (1) · Sheba Medical Center (1) · Sykehuset i Vestfold HF (1) · Taproot Health (1) · University Hospital, Ghent (1) · University of California, Davis (1) · Weill Medical College of Cornell University (1) · xCures (1)
United States (9) · Belgium (2) · Finland (1) · France (1) · Germany (1) · Israel (1) · Italy (1) · Norway (1) · Poland (1) · Switzerland (1) · United Kingdom (1)
Dejan Ignjatovic, MD PhD (1) · Edward Kim, MD, PhD (1) · Gabriel A Brooks, M.D. (1) · Gabriel A Brooks, MD (1) · Heather Yeo, MD (1) · Heikki Joensuu, MD (1) · Jennifer A. Chan, MD, MPH (1) · Jennifer Johnson, MD, PhD (1) · Matthias Guckenberger (1) · Nicholas D Klemen, M.D. (1) · Ofer Margali, MD PhD (1) · Piet Ost (1) · Raymond Bergan, MD (1) · Razelle Kurzrock, MD (1) · Vivek Subbiah, MD (1)
PMID 29149611, PMID 39936801, PMID 40624418, PMID 40779182
P30CA093373 (1)